Insider Trading Alert - NATI, FRX, AMTD, AEO And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 27, 2014, 48 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $206.00 to $52,812,000.00.

Highlighted Stocks Traded by Insiders:

National Instruments Corporation (NATI) - FREE Research Report

Kodosky Jeffrey L who is Director at National Instruments Corporation sold 4,000 shares at $32.63 on Jan. 27, 2014. Following this transaction, the Director owned 969,180 shares meaning that the stake was reduced by 0.41% with the 4,000-share transaction.

The shares most recently traded at $31.45, down $1.18, or 3.74% since the insider transaction. Historical insider transactions for National Instruments Corporation go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 27,271
  • 24-Week # shares sold: 75,271

The average volume for National Instruments Corporation has been 357,400 shares per day over the past 30 days. National Instruments Corporation has a market cap of $4.0 billion and is part of the technology sector and computer software & services industry. Shares are down 2.53% year-to-date as of the close of trading on Monday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. It offers LabVIEW, a system design software product for measurement and control; and LabVIEW Real-Time and LabVIEW FPGA that are strategic modular software add-ons. The stock currently has a dividend yield of 1.76%. The company has a P/E ratio of 58.0. Currently there is 1 analyst that rates National Instruments Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full National Instruments Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Forest Laboratories (FRX) - FREE Research Report

Solomon Howard who is Director at Forest Laboratories sold 250,000 shares at $65.41 on Jan. 27, 2014. Following this transaction, the Director owned 464,881 shares meaning that the stake was reduced by 34.97% with the 250,000-share transaction.

The shares most recently traded at $65.19, down $0.22, or 0.33% since the insider transaction. Historical insider transactions for Forest Laboratories go as follows:

  • 4-Week # shares sold: 250,000
  • 12-Week # shares sold: 250,000
  • 24-Week # shares sold: 263,104

The average volume for Forest Laboratories has been 2.1 million shares per day over the past 30 days. Forest Laboratories has a market cap of $17.5 billion and is part of the health care sector and drugs industry. Shares are up 8.51% year-to-date as of the close of trading on Monday.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company has a P/E ratio of 114.0. Currently there are 11 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRX - FREE

TheStreet Quant Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TD Ameritrade Holding Corporation (AMTD) - FREE Research Report

Moglia Joseph H who is Director at TD Ameritrade Holding Corporation sold 106,753 shares at $32.60 on Jan. 27, 2014. Following this transaction, the Director owned 628,915 shares meaning that the stake was reduced by 14.51% with the 106,753-share transaction.

Nally Thomas A. who is Exec. VP, inst'l svcs at TD Ameritrade Holding Corporation sold 9,000 shares at $33.51 on Jan. 27, 2014. Following this transaction, the Exec. VP, inst'l svcs owned 157,297 shares meaning that the stake was reduced by 5.41% with the 9,000-share transaction.

The shares most recently traded at $31.63, down $1.88, or 5.94% since the insider transaction. Historical insider transactions for TD Ameritrade Holding Corporation go as follows:

  • 4-Week # shares sold: 65,084
  • 12-Week # shares sold: 5.7 million
  • 24-Week # shares sold: 5.7 million

The average volume for TD Ameritrade Holding Corporation has been 2.2 million shares per day over the past 30 days. TD Ameritrade Holding Corporation has a market cap of $17.6 billion and is part of the financial sector and financial services industry. Shares are up 2.48% year-to-date as of the close of trading on Monday.

TD Ameritrade Holding Corporation provides securities brokerage services and technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 24.6. Currently there are 7 analysts that rate TD Ameritrade Holding Corporation a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMTD - FREE

TheStreet Quant Ratings rates TD Ameritrade Holding Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full TD Ameritrade Holding Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

American Eagle Outfitters (AEO) - FREE Research Report

Schottenstein Jay L who is Executive Chairman of the Boar at American Eagle Outfitters bought 500,000 shares at $12.84 on Jan. 27, 2014. Following this transaction, the Executive Chairman of the Boar owned 2.5 million shares meaning that the stake was reduced by 24.58% with the 500,000-share transaction.

Spiegel Noel Joseph who is Director at American Eagle Outfitters bought 5,000 shares at $13.21 on Jan. 27, 2014. Following this transaction, the Director owned 5,000 shares meaning that the stake was reduced by 100% with the 5,000-share transaction.

The shares most recently traded at $13.26, up $0.05, or 0.38% since the insider transaction. Historical insider transactions for American Eagle Outfitters go as follows:

  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 54,464

The average volume for American Eagle Outfitters has been 5.3 million shares per day over the past 30 days. American Eagle Outfitters has a market cap of $2.5 billion and is part of the services sector and retail industry. Shares are down 11.32% year-to-date as of the close of trading on Monday.

American Eagle Outfitters, Inc., together with its subsidiaries, operates as an apparel and accessories retailer in the United States and Canada. The stock currently has a dividend yield of 3.92%. The company has a P/E ratio of 15.2. Currently there are 5 analysts that rate American Eagle Outfitters a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AEO - FREE

TheStreet Quant Ratings rates American Eagle Outfitters as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full American Eagle Outfitters Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 37,000 shares at $8.51 on Jan. 27, 2014. Following this transaction, the CEO & Chairman owned 138.0 million shares meaning that the stake was reduced by 0.03% with the 37,000-share transaction.

The shares most recently traded at $8.11, down $0.40, or 4.91% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.4 million shares per day over the past 30 days. Opko Health has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are down 3.67% year-to-date as of the close of trading on Monday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

National Instruments Has More Room on the Upside

National Instruments Has More Room on the Upside

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Insiders Are Scooping Up These 5 Stocks Right Now

Insiders Are Scooping Up These 5 Stocks Right Now

Insider Trading Alert - NATI, PCLN And LQ Traded By Insiders

Insider Trading Alert - NATI, PCLN And LQ Traded By Insiders

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales